Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Opportunities to Optimize Cancer Policies Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Advertisement

Advertisement




Aug
17
Today In Oncology
AI Model Predicts TP53 Status Tumor Type and Survival From Routine HE Slides
AASLD Publishes Landmark North American Framework to Advance Treatment Decisions for HCC
Adding Irinotecan to Preoperative Chemoradiotherapy Does Not Improve Outcomes in Locally Advanced Rectal Cancer
Early Intravesical Pirarubicin Improves Relapse-Free Survival in Upper Tract Urothelial Carcinoma
Darovasertib Plus Crizotinib May Set New First-Line Standard in HLA-A2–Negative Metastatic Uveal Melanoma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo